{"id":56912,"date":"2026-02-11T22:34:16","date_gmt":"2026-02-11T14:34:16","guid":{"rendered":"https:\/\/flcube.com\/?p=56912"},"modified":"2026-02-11T22:34:18","modified_gmt":"2026-02-11T14:34:18","slug":"sciclones-tasurgratinib-nda-accepted-by-nmpa-for-fgfr2-biliary-tract-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56912","title":{"rendered":"SciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer"},"content":{"rendered":"\n

SciClone Pharmaceuticals Inc.<\/strong> (HKG:\u202f6600<\/a><\/strong>) announced that the National Medical Products Administration (NMPA)<\/strong> has accepted for review<\/strong> its New Drug Application (NDA)<\/strong> for tasurgratinib succinate (E7090)<\/strong>, a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor<\/strong> licensed from Eisai Co., Ltd.<\/strong> (TYO:\u202f4523<\/a><\/strong>). The filing seeks approval for unresectable biliary tract cancer<\/strong> with FGFR2 fusion\/rearrangement<\/strong> following prior chemotherapy progression<\/strong>\u2014a biomarker-defined orphan indication<\/strong> with no approved targeted therapies in China<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Filing Company<\/strong><\/td>SciClone Pharmaceuticals Inc. (HKG:\u202f6600)<\/td><\/tr>
Originator<\/strong><\/td>Eisai Co., Ltd. (Tokyo:\u202f4523, Japan)<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Asset<\/strong><\/td>Tasurgratinib succinate (E7090) \u2013 FGFR1\/2\/3 TKI<\/td><\/tr>
Trade Name (Japan)<\/strong><\/td>Tasfygo (approved September\u202f2024)<\/td><\/tr>
Target Indication<\/strong><\/td>Unresectable biliary tract cancer with FGFR2 fusion\/rearrangement; post-chemotherapy progression<\/td><\/tr>
Licensing Deal<\/strong><\/td>February\u202f2025 \u2013 SciClone secured exclusive China rights<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Biology & Mechanism<\/h2>\n\n\n\n
Feature<\/th>Tasurgratinib Specification<\/th>Clinical Rationale<\/th><\/tr><\/thead>
Kinase Selectivity<\/strong><\/td>FGFR1, FGFR2, FGFR3 inhibition<\/strong><\/td>Broad FGFR coverage; FGFR2 fusion-specific efficacy<\/td><\/tr>
Driver Mutations<\/strong><\/td>FGFR2-AHCYL1, FGFR2-BICC1, FGFR2-TXLNA, FGFR2-KCTD1 fusions\/rearrangements<\/td>Oncogene addiction<\/strong> in cholangiocarcinoma; constitutive FGFR2 activation<\/td><\/tr>
Mechanism<\/strong><\/td>Blocks constitutively activated FGFR2 signaling<\/td>Tumor growth inhibition; apoptosis induction<\/td><\/tr>
Japan Validation<\/strong><\/td>Approved September\u202f2024<\/strong> as Tasfygo<\/td>Regulatory precedent; established efficacy\/safety profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Positioning<\/h2>\n\n\n\n
Factor<\/th>Market Analysis<\/th><\/tr><\/thead>
Biliary Tract Cancer Burden<\/strong><\/td>>180,000 new cases annually in China<\/strong>; 10-15% harbor FGFR2 fusions\/rearrangements<\/strong> \u2013 addressable population ~18,000-27,000 patients<\/td><\/tr>
Unmet Need<\/strong><\/td>No approved FGFR inhibitors in China<\/strong> for biliary cancer; standard chemotherapy (gemcitabine\/cisplatin) offers limited durability<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Pemigatinib (Incyte)<\/strong> and futibatinib (Taiho)<\/strong> approved in US\/EU; tasurgratinib first Japan-approved, now China-bound<\/strong><\/td><\/tr>
SciClone Strategy<\/strong><\/td>In-licensing proven assets<\/strong> from Japanese innovators (Eisai, Taiho); leverages regulatory expertise and hospital relationships<\/strong> for rapid commercialization<\/td><\/tr>
Biomarker-Defined Market<\/strong><\/td>Companion diagnostic requirement<\/strong> creates prescription control<\/strong> and premium pricing<\/strong> vs. chemotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercial Outlook<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>NDA under NMPA review<\/td>2026<\/td><\/tr>
Approval<\/strong><\/td>Marketing authorization anticipated<\/td>2026-2027<\/strong><\/td><\/tr>
Launch<\/strong><\/td>Hospital oncology access; biomarker testing partnership<\/td>2027<\/td><\/tr>
Expansion<\/strong><\/td>Potential label expansion to other FGFR-driven malignancies (urothelial, gastric)<\/td>Post-approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding tasurgratinib NMPA approval timelines, SciClone’s commercial execution in biliary tract cancer, and competitive dynamics with pemigatinib and futibatinib in China. Actual results may differ due to regulatory review delays, FGFR2 biomarker testing adoption rates, and pricing negotiations with national reimbursement programs.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

SciClone Pharmaceuticals Inc. (HKG:\u202f6600) announced that the National Medical Products Administration (NMPA) has accepted for…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,350,932,38,152,1151],"class_list":["post-56912","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-eisai","tag-hkg-6600","tag-market-approval-filings","tag-sciclone-pharmaceuticals","tag-tyo-4523"],"yoast_head":"\nSciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SciClone Pharmaceuticals Inc. (HKG:\u202f6600) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for tasurgratinib succinate (E7090), a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor licensed from Eisai Co., Ltd. (Tokyo:\u202f4523). The filing seeks approval for unresectable biliary tract cancer with FGFR2 fusion\/rearrangement following prior chemotherapy progression\u2014a biomarker-defined orphan indication with no approved targeted therapies in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56912\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer\" \/>\n<meta property=\"og:description\" content=\"SciClone Pharmaceuticals Inc. (HKG:\u202f6600) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for tasurgratinib succinate (E7090), a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor licensed from Eisai Co., Ltd. (Tokyo:\u202f4523). The filing seeks approval for unresectable biliary tract cancer with FGFR2 fusion\/rearrangement following prior chemotherapy progression\u2014a biomarker-defined orphan indication with no approved targeted therapies in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56912\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T14:34:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T14:34:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56912#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56912\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer\",\"datePublished\":\"2026-02-11T14:34:16+00:00\",\"dateModified\":\"2026-02-11T14:34:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56912\"},\"wordCount\":378,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Eisai\",\"HKG: 6600\",\"Market approval filings\",\"SciClone Pharmaceuticals\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56912#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56912\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56912\",\"name\":\"SciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-11T14:34:16+00:00\",\"dateModified\":\"2026-02-11T14:34:18+00:00\",\"description\":\"SciClone Pharmaceuticals Inc. (HKG:\u202f6600) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for tasurgratinib succinate (E7090), a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor licensed from Eisai Co., Ltd. (Tokyo:\u202f4523). The filing seeks approval for unresectable biliary tract cancer with FGFR2 fusion\\\/rearrangement following prior chemotherapy progression\u2014a biomarker-defined orphan indication with no approved targeted therapies in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56912#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56912\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56912#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer - Insight, China's Pharmaceutical Industry","description":"SciClone Pharmaceuticals Inc. (HKG:\u202f6600) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for tasurgratinib succinate (E7090), a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor licensed from Eisai Co., Ltd. (Tokyo:\u202f4523). The filing seeks approval for unresectable biliary tract cancer with FGFR2 fusion\/rearrangement following prior chemotherapy progression\u2014a biomarker-defined orphan indication with no approved targeted therapies in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56912","og_locale":"en_US","og_type":"article","og_title":"SciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer","og_description":"SciClone Pharmaceuticals Inc. (HKG:\u202f6600) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for tasurgratinib succinate (E7090), a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor licensed from Eisai Co., Ltd. (Tokyo:\u202f4523). The filing seeks approval for unresectable biliary tract cancer with FGFR2 fusion\/rearrangement following prior chemotherapy progression\u2014a biomarker-defined orphan indication with no approved targeted therapies in China.","og_url":"https:\/\/flcube.com\/?p=56912","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-11T14:34:16+00:00","article_modified_time":"2026-02-11T14:34:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56912#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56912"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer","datePublished":"2026-02-11T14:34:16+00:00","dateModified":"2026-02-11T14:34:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56912"},"wordCount":378,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Eisai","HKG: 6600","Market approval filings","SciClone Pharmaceuticals","TYO: 4523"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56912#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56912","url":"https:\/\/flcube.com\/?p=56912","name":"SciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-11T14:34:16+00:00","dateModified":"2026-02-11T14:34:18+00:00","description":"SciClone Pharmaceuticals Inc. (HKG:\u202f6600) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for tasurgratinib succinate (E7090), a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor licensed from Eisai Co., Ltd. (Tokyo:\u202f4523). The filing seeks approval for unresectable biliary tract cancer with FGFR2 fusion\/rearrangement following prior chemotherapy progression\u2014a biomarker-defined orphan indication with no approved targeted therapies in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56912#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56912"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56912#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SciClone\u2019s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56912"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56912\/revisions"}],"predecessor-version":[{"id":56914,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56912\/revisions\/56914"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}